References
- Deruddre S, Cheisson G, Mazoit J-X, Vicaut E, Benhamou D, Duranteau J. 2007. Renal arterial resistance in septic shock: effects of increasing mean arterial pressure with norepinephrine on the renal resistive index assessed with Doppler ultrasonography. Intensive Care Med. 33(9):1557–1562.
- [DMDG] Drug Metabolism Discussion Group 2021. Available from: www.dmdg.org. [last accessed 8 December ].
- Dubin A, Pozo MO, Casabella CA, Pálizas F, Jr, Murias G, Moseinco MC, Edul VSK, Pálizas F, Estenssoro E, Ince C. 2009. Increasing arterial blood pressure with norepinephrine does not improve microcirculatory blood flow: a prospective study. Crit Care. 13(3):R92.
- Esposito S, de Leonibus ML, Ingenito R, Bianchi E, Orsatti L, Monteagudo E. 2018. A liquid chromatography high-resolution mass spectrometry in vitro assay to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. J Pharm Biomed. 159:449–458.
- [EMA] European Medicines Agency 2012. Guideline on the investigation of drug interactions, Available from: www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf. [last accessed 8 December 2021].
- Fellner RC, Terryah ST, Tarran R. 2016. Inhaled protein/peptide-based therapies for respiratory disease. Mol Cell Pediatr. 3(1):16.
- Henderson CJ, Kapelyukh Y, Scheer N, Rode A, McLaren AW, MacLeod AK, Lin D, Wright D, Stanley LA, Wolf CR. 2019. An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials. Drug Metab Dispos. 47(6):601–615.
- Jhanji S, Stirling S, Patel N, Hinds CJ, Pearse RM. 2009. The effect of increasing doses of norepinephrine on tissue oxygenation and microvascular flow in patients with septic shock. Crit Care Med. 37(6):1961–1966.
- Moriya Y, Kogame A, Tagawa Y, Morohashi A, Kondo T, Asahi S, Benet LZ. 2019. The enhancement of subcutaneous first-pass metabolism causes nonlinear pharmacokinetics of TAK-448 after a single subcutaneous administration to rats. Drug Metab Dispos. 47(9):1004–1012.
- NCT01000649 2021. Effects of the V1a Agonist FE 202158 in patients with septic shock. [Accessed 8 December]. Available from: https://clinicaltrials.gov/ct2/show/NCT01000649?term=NCT01000649&draw=2&rank=1
- NCT01612676 2021. Investigating FE 202158 as potential primary treatment in patients with early septic shock [Accessed 8 December]. Available from: https://clinicaltrials.gov/ct2/show/NCT01612676?term=NCT01612676&draw=2&rank=1
- Russel JA, Vincent J-L, Kjølbye AL, Olsson H, Blemings A, Spapen H, Carl P, Laterre P-F, Grundemar L. 2017. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care. 21(1):213.
- Sala V, Cnudde SJ, Murabito A, Massarotti A, Hirsch E, Ghigo A. 2021. Therapeutic peptides for the treatment of cystic fibrosis: Challenges and perspectives. Eur J Med Chem. 213:113191.
- Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. 2012. Introduction to drug pharmacokinetics in the critically ill patient. Chest. 141(5):1327– 1336.
- Sonesson A, Bjørnsdottir I, Christensen JK. 2021. Meeting report: 2nd Workshop of the Peptide ADME Discussion Group. Xenobiotica. 51(1):1–4.
- Sonesson A, Brady K, Bjørnsdottir I, Christensen JK. 2021. Meeting report: 1st Workshop of the Peptide ADME Discussion Group. Xenobiotica. 51(1):122–125.
- [FDA] US Food and Drug Administration 2020a. Clinical Drug Interaction Studies - Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry. [Accessed 8 December 2021]. www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions
- [FDA] US Food and Drug Administration 2020b. In Vitro Drug Interaction Studies- Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions. [Accessed 8 December 2021]. www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions
- [FDA] US Food and Drug Administration 2020c. Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry. Draft guideline [Accessed 8 December 2021]. www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-drug-interaction-assessment-therapeutic-proteins-guidance-industry
- Valeur E, Guéret SM, Adihou H, Gopalakrishnan R, Lemurell M, Waldmann H, Grossmann TN, Plowright AT. 2017. New modalities for challenging targets in drug discovery. Angew Chem Int Ed Engl. 56(35):10294–10323.